Tag Archives: Germany

Germany Post AMNOG

While emerging markets continue to represent a new channel of demand for pharmaceutical products, manufacturers have quickly realized that significant attention must still be given to more established markets, such as Germany. It’s no longer sufficient to expect that regulatory data from prospective randomized clinical studies alone will be enough to convince payers to provide […]
Posted in Europe, Guest Blog, pricing | Also tagged , , , | Leave a comment

Type 2 Diabetes Opportunities in Europe "Vast", Says Report

“Vast” Diabetes Opportunities in Europe, Says Report The European type 2 diabetes market earned revenues of €9.50 billion in 2009 and is estimated to reach €15.46 billion in 2017 (CAGR 3.8 percent), according to new research by Frost & Sullivan. The International Diabetes Federation states that more than 55 million people have been diagnosed with […]
Posted in Europe, healthcare | Also tagged , , , , , , , | Leave a comment

Orphan Drug Adoption: the More Regulation, the Better

New survey research indicates that a country with a strong regulatory commitment for advancing drugs for rare diseases does better in getting orphan drugs to patients than countries with lesser regulatory frameworks. In his study, ‘The Effect of Market-Based Economic Factors on the Adoption of Orphan Drugs Across Multiple Countries,’ John Matthews, Associate Director of […]
Posted in Europe, Global, Market Access, Orphan Drugs, pricing, Regulatory | Also tagged , , , , , | Leave a comment

Those Amazing 'Gold Plated, Cadillac Care' Drug Programs

by Tom Norton Not too many years ago, while employed by one of America’s leading Rx manufacturers, I remember stepping up to a retail drug store counter to pick up a prescription.  As the pharmacist handed me my script, he said, “Wow.  I don’t know what kind of health insurance you have, but I have […]
Posted in FDA, Global, Guest Blog, healthcare, Legal, Market Access, pricing, Regulatory, Strategy | Also tagged , , , , , , , , , , , , , , , , , | Leave a comment
  • Categories

  • Meta